产品分类导航
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management

Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management

更新时间:2025-06-20

立即询盘
收藏

产品详情

产品名称: Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
产品分类: 其他生物制剂
CAS号: 910463-68-2
药典: 中国药典,企业标准
级别: injection
产品关键词: GLP-1 Agonist,Type 2 Diabetes Treatment,Weight Loss Therapy,Once- DWeeklyosing,Long-Acting Medication
是否为生产商:
产品包装规格: 2mg/Ampoule 10mg/Ampoule 15mg/Ampoule 10Ampoules/Box
主要销售市场: 中国,北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲

产品描述:


Mechanism of Action

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the effects of endogenous GLP-1. It works through several key mechanisms:

  1. Glucose-Dependent Insulin Secretion: Semaglutide stimulates insulin secretion from pancreatic β-cells in a glucose-dependent manner, enhancing glucose homeostasis.
  2. Inhibition of Glucagon Secretion: It reduces the secretion of glucagon from pancreatic α-cells, decreasing hepatic gluconeogenesis and maintaining stable blood glucose levels.
  3. Delayed Gastric Emptying: Semaglutide slows down gastric emptying, which helps reduce postprandial blood glucose spikes and contributes to a feeling of satiety.
  4. Appetite Regulation: By acting on the central nervous system, semaglutide activates anorexigenic signaling pathways, reducing food intake and promoting weight loss.
  5. Anti-Inflammatory and Antioxidant Effects: Semaglutide modulates inflammation and oxidative stress through pathways such as AMPK/SIRT1, reducing the activity of pro-inflammatory factors like NF-κB.

Applications

  1. Type 2 Diabetes Management: Semaglutide is used to improve glycemic control in adults with type 2 diabetes mellitus.
  2. Weight Management: It is also indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
  3. Cardiovascular Risk Reduction: Semaglutide has been shown to reduce the risk of major adverse cardiovascular events in patients with established cardiovascular disease.

Dosage Instructions

  1. Initial Dose: Start with a 0.25 mg subcutaneous injection once weekly for the first 4 weeks.
  2. Maintenance Dose: After 4 weeks, increase the dose to 0.5 mg once weekly. If additional glycemic control is needed, the dose can be increased to 1 mg once weekly.
  3. Injection Instructions: Administer semaglutide subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.
  4. Missed Dose: If a dose is missed, administer as soon as possible within 5 days. If more than 5 days have passed, skip the missed dose and resume the regular schedule.

Storag

  1. Unopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.
  2. Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.
  3. Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.

公司简介

上海浦津林州制药有限公司,始建于1974年,其前身是林州市市属工业企业--安阳市化学制药厂, 2015年9月更名为“上海浦津林州制药有限公司” 公司位于风景秀丽的太行山东麓,举世闻名的人工天河——红旗渠畔,交通便利,通讯发达。公司占地面积5.5万m2,建筑面积1.9万m2,其中仓储面积3000 m2;厂区绿化面积16000 m2,硬化面积8000 m2。现有职工300余人,固定资产总值6418万元,主导产品主要有葡萄糖酸钙、硫酸镁、维生素C、肌苷等35个注射液品种,在市场上深受广大客户青睐,市场前景广阔。公司为了进一步扩大生产规模,提升产品档次,提高市场占有率,先后投资3.6亿余元,进行技术改造,现在拥有12条符合国家GMP标准的小容量注射剂全自动生产线,并于2014年5月通过国家食品药品监督管理局GMP认证;新建车间年设计生产能力12亿支,可实现产值3亿多元,利税5000余万元。 近年来,公司创新意识不断增强,始终把“技术创新,科技兴厂”作为公司发展的宗旨,企业发展空间大、前景广阔,愿各界同仁、有识之士携手并进,共谋美好未来。

该公司其他产品

Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Mechanism of ActionSemaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the effects of endogenous GLP-1. It works through several key mechanisms:Glucose-Dependent Insulin Secretion: Semaglutide stimulates insulin secretion from pancreatic β-cells in a glucose-dependent manner, enhancing glucose homeostasis.Inhibition of Glucagon Secretion: It reduces the secretion of glucagon from pancreatic α-cells, decreasing hepatic gluconeogenesis and maintaining stable blood glucose levels.Delayed Gastric Emptying: Semaglutide slows down gastric emptying, which helps reduce postprandial blood glucose spikes and contributes to a feeling of satiety.Appetite Regulation: By acting on the central nervous system, semaglutide activates anorexigenic signaling pathways, reducing food intake and promoting weight loss.Anti-Inflammatory and Antioxidant Effects: Semaglutide modulates inflammation and oxidative stress through pathways such as AMPK/SIRT1, reducing the activity of pro-inflammatory factors like NF-κB.ApplicationsType 2 Diabetes Management: Semaglutide is used to improve glycemic control in adults with type 2 diabetes mellitus.Weight Management: It is also indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.Cardiovascular Risk Reduction: Semaglutide has been shown to reduce the risk of major adverse cardiovascular events in patients with established cardiovascular disease.Dosage InstructionsInitial Dose: Start with a 0.25 mg subcutaneous injection once weekly for the first 4 weeks.Maintenance Dose: After 4 weeks, increase the dose to 0.5 mg once weekly. If additional glycemic control is needed, the dose can be increased to 1 mg once weekly.Injection Instructions: Administer semaglutide subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.Missed Dose: If a dose is missed, administer as soon as possible within 5 days. If more than 5 days have passed, skip the missed dose and resume the regular schedule.StoragUnopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.
Liraglutide for Weight Loss: Harnessing the Power of GLP-1 Receptor Agonism
Liraglutide for Weight Loss: Harnessing the Power of GLP-1 Receptor Agonism
Mechanism of ActionSemaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the effects of endogenous GLP-1. It works through several key mechanisms:Glucose-Dependent Insulin Secretion: Semaglutide stimulates insulin secretion from pancreatic β-cells in a glucose-dependent manner, enhancing glucose homeostasis.Inhibition of Glucagon Secretion: It reduces the secretion of glucagon from pancreatic α-cells, decreasing hepatic gluconeogenesis and maintaining stable blood glucose levels.Delayed Gastric Emptying: Semaglutide slows down gastric emptying, which helps reduce postprandial blood glucose spikes and contributes to a feeling of satiety.Appetite Regulation: By acting on the central nervous system, semaglutide activates anorexigenic signaling pathways, reducing food intake and promoting weight loss.Anti-Inflammatory and Antioxidant Effects: Semaglutide modulates inflammation and oxidative stress through pathways such as AMPK/SIRT1, reducing the activity of pro-inflammatory factors like NF-κB.ApplicationsType 2 Diabetes Management: Semaglutide is used to improve glycemic control in adults with type 2 diabetes mellitus.Weight Management: It is also indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.Cardiovascular Risk Reduction: Semaglutide has been shown to reduce the risk of major adverse cardiovascular events in patients with established cardiovascular disease.Dosage InstructionsInitial Dose: Start with a 0.25 mg subcutaneous injection once weekly for the first 4 weeks.Maintenance Dose: After 4 weeks, increase the dose to 0.5 mg once weekly. If additional glycemic control is needed, the dose can be increased to 1 mg once weekly.Injection Instructions: Administer semaglutide subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.Missed Dose: If a dose is missed, administer as soon as possible within 5 days. If more than 5 days have passed, skip the missed dose and resume the regular schedule.StoragUnopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.
Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control
Retatrutide: Triple-Action Agonist for Weight Loss and Diabetes Control
Mechanism of ActionSemaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the effects of endogenous GLP-1. It works through several key mechanisms:Glucose-Dependent Insulin Secretion: Semaglutide stimulates insulin secretion from pancreatic β-cells in a glucose-dependent manner, enhancing glucose homeostasis.Inhibition of Glucagon Secretion: It reduces the secretion of glucagon from pancreatic α-cells, decreasing hepatic gluconeogenesis and maintaining stable blood glucose levels.Delayed Gastric Emptying: Semaglutide slows down gastric emptying, which helps reduce postprandial blood glucose spikes and contributes to a feeling of satiety.Appetite Regulation: By acting on the central nervous system, semaglutide activates anorexigenic signaling pathways, reducing food intake and promoting weight loss.Anti-Inflammatory and Antioxidant Effects: Semaglutide modulates inflammation and oxidative stress through pathways such as AMPK/SIRT1, reducing the activity of pro-inflammatory factors like NF-κB.ApplicationsType 2 Diabetes Management: Semaglutide is used to improve glycemic control in adults with type 2 diabetes mellitus.Weight Management: It is also indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.Cardiovascular Risk Reduction: Semaglutide has been shown to reduce the risk of major adverse cardiovascular events in patients with established cardiovascular disease.Dosage InstructionsInitial Dose: Start with a 0.25 mg subcutaneous injection once weekly for the first 4 weeks.Maintenance Dose: After 4 weeks, increase the dose to 0.5 mg once weekly. If additional glycemic control is needed, the dose can be increased to 1 mg once weekly.Injection Instructions: Administer semaglutide subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.Missed Dose: If a dose is missed, administer as soon as possible within 5 days. If more than 5 days have passed, skip the missed dose and resume the regular schedule.StoragUnopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.
上海浦津林州制药有限公司
注册资本
联系人
查看联系方式
快速询盘
询盘主题
请输入询盘主题
询盘信息
请输入询盘信息
快速发送询盘
2006-2026 上海博华国际展览有限公司版权所有(保留一切权利) 沪ICP备05034851号-57